TW201722462A - 具有包含GcMAF之配方之乾燥劑型之片劑形式或膠囊形式之產品 - Google Patents
具有包含GcMAF之配方之乾燥劑型之片劑形式或膠囊形式之產品 Download PDFInfo
- Publication number
- TW201722462A TW201722462A TW105135919A TW105135919A TW201722462A TW 201722462 A TW201722462 A TW 201722462A TW 105135919 A TW105135919 A TW 105135919A TW 105135919 A TW105135919 A TW 105135919A TW 201722462 A TW201722462 A TW 201722462A
- Authority
- TW
- Taiwan
- Prior art keywords
- capsule
- gcmaf
- product
- formulation
- tablet
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 30
- 108010063191 vitamin D-binding protein-macrophage activating factor Proteins 0.000 title claims abstract description 25
- 102100038611 Vitamin D-binding protein Human genes 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000009472 formulation Methods 0.000 title claims abstract description 15
- 239000002552 dosage form Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 15
- 239000002274 desiccant Substances 0.000 claims description 9
- 210000004051 gastric juice Anatomy 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 description 19
- 239000007921 spray Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 210000003022 colostrum Anatomy 0.000 description 4
- 235000021277 colostrum Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000873 masking effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CMSYVPIXXGNYEG-KEWYIRBNSA-N N'-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetohydrazide Chemical compound CC(=O)NN[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O CMSYVPIXXGNYEG-KEWYIRBNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 102100028756 Sialidase-3 Human genes 0.000 description 1
- 108050000176 Sialidase-3 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000020184 organic milk Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C1/00—Concentration, evaporation or drying
- A23C1/04—Concentration, evaporation or drying by spraying into a gas stream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/14—Drying
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本發明涉及一片劑形式或一以膠囊形式之產品，其中每一產品皆由包含GcMAF之配方之乾燥劑型所組成。
Description
本發明揭露一產品具有申請專利範圍第1項之特徵，和一產品具有申請專利範圍第4項之特徵。
GcMAF，亦稱為DBP-MAF，為巨噬細胞活化因子(MAF)，其於人體內由DBP(維生素D結合蛋白質之縮寫)酶化所產生；此處DBP是一醣蛋白，其具有約58,000道耳頓之分子量，屬於白蛋白族群，其在血液裡大量存在，其中該DBP與維生素D衍生物結合，並在血液中轉運傳送。該DBP-血液濃度約為300-600微克/毫升。糖側鏈由N-乙醯半乳胺糖組成，其由半乳糖和唾液酸交聯生成。免疫活化之後，GC蛋白之糖鏈被由B細胞之誘導性細胞膜β-半乳糖苷酶水解，而形成巨噬細胞前活化因子。此前活化因子蛋白然後經由已活化T細胞之細胞膜唾液酸酶(神經胺酸酶)水解為具有N-乙醯半乳胺糖(GaINAc)作為剩餘殘糖之最終GcMAF。此N-乙醯半乳胺糖(GaINAc)是GcMAF發揮效益之關鍵。
此酵素「Nagalase」(alpha-N-Acetylgalactosaminidase)屬於肝臟中一種溶酶體酵素，其切割GaINAc和蛋白質之蘇胺酸或絲胺酸殘基之間鍵結。該Nagalase酵素可以切割Gc蛋白之糖側鏈，由此失去其前體活性並
且不能轉化為活性GcMAF。此外，Nagalase亦透過糖裂解使活性GcMAF失去活性。
巨噬細胞在免疫防禦中佔據一關鍵作用，並且以來自骨髓之年輕未成熟單核細胞進入血液。在血液中其差異分化成樹突狀細胞或在活化作用之後，進入組織，在那裡成熟為常駐組織之巨噬細胞，然後依組織被作為庫弗式星狀細胞(肝)，神經膠質細胞(神經系統)，肺泡巨噬細胞(肺)，蝕骨細胞(骨)，或朗罕氏巨細胞(皮膚)。
此GcMAF顯然有巨大潛力針對單核細胞和巨噬細胞之活化。即使是最低濃度刺激氧自由基之抗菌產物，其單核細胞之「氧化爆發」高達50倍。吞噬活性能力和HLA分子表現增加到100倍，其抗原呈現可以成指數成長。通過此增強效應，可以更有效地打擊在此之前僅受限之病原體於免疫缺陷。此可以活化對無法識別抗原之免疫反應。可以分解和殺死，已被免疫識別之腫瘤細胞。在過去幾年中，已確認GcMAF已經能夠治療腫瘤疾病和感染，例如HIV。
GC-MAF係根據藥品法規管理，因為其以靜脈注射藥。由於該製劑還沒有被批准作為藥品，僅能根據德國藥用產品規範之法律第13條(Gesetz über den Verkehr mit Arzneimitteln)，經由醫師在自我生產規範內應用到患者。其先決條件如下：■透過開業許可證明和醫師號數之呈交，行使醫療專業之資格，■經由醫師監督，在合同實驗室生產，
■在外國實驗室分析之研究，其證明該蛋白質之絕對純度和無危險性，和■活性證明。
GcMAF目前可透過主治醫師依下列三種給藥形式，自主生產■靜脈注射，■以優格狀型式(口服給藥或作為栓劑)或，■以冷凍乾燥之型式(舌下)。
因此，本發明之目的係提供根據包含GcMAF之配方之乾燥劑型之產品，使其不必由主治醫師之自行製造。
該目的係經由具有申請專利範圍第1項特徵之一片劑和具有申請專利範圍第4項特徵之一膠囊得以實現。
本發明之優點
根據本發明之產品具有相對之優點，該片劑由包含GcMAF之配方之乾燥劑型所組成，其中以其許可方式改善用於人類之劑型，因此同樣具有生產成本效益。進一步之優點為，乾燥劑型發揮高生物活性之免疫調節作用，因此可以降低給藥頻率。
一乾燥劑型優點，例如：保存期較長，氧化敏感性較低，可經由乾燥本身，或者作為以下乾燥材料之進一步加工，以定義和調節顆粒結構，
■粉末(塗層，非塗層，抗胃液性，遮蔽味道，或類似者)，■顆粒(塗層，非塗層，抗胃液性，遮蔽味道，或類似者)，■丸(塗層，非塗層，抗胃液性，遮蔽味道，或類似者)，■擠出物(塗層，非塗層，抗胃液性，遮蔽味道，或類似者)，■栓塞劑，及■微粉化後之細粉(例如，經由研磨)。
此外，該作用機制和作用部位經藉由所述配方或劑型可自由調節。劑量可經由所述配方劑型輕鬆調節，由此實現安全之應用和預防錯誤。
此外，此固體劑型可作為膳食補充劑、保健食品被商業化出售，因此，可安全處理(無需製藥環境)。
進一步優點，其活性物質維持精細分散(微粉化)，即相較於已知劑型，表面積顯著增加，因此可更快被體內攝取，例如，口服給藥通過口腔粘膜之途徑。
蛋白質(GcMAF)及來自發酵之微生物或酵母之同時存在，亦為優點之一。這些都與乾燥之GcMAF並行存在，並且可以在應用中恢復活性。此外，協同作用被使用，例如作為在小腸內之益生菌(較佳之總菌群或類似物)。
根據本發明產品之有利實施例，其片劑至少包括一塗層，所述之塗層，其可抵抗胃液和/或遮蔽味道。而可作為，例如，可以精確地調節其作用時間或作用位置。確保該片劑經由一抗胃液塗層，可通過胃通
道。一掩味塗層，以確保覆蓋該片劑之某些味道。
根據本發明之產品具有相對之優點，該片劑由含GcMAF之配方之乾燥劑型所組成，其中以其許可方式改善人類對於製藥呈現方式，因此同樣具有生產成本效益。進一步之優點為，乾燥劑型發揮高生物活性之免疫調節作用，因此可以降低給藥頻率。一膠囊是一固體藥物劑型，其富含一已確定劑量之藥物或活性成分。膠囊通常應用於口服，但亦有應用於陰道或直腸之膠囊。膠囊通常由膠囊殼和填充物組成。膠囊殼通常由明膠，纖維素或鹿角菜膠，澱粉或黏膠組成。於某些藥物，一抗胃液塗層，被塗覆於軟明膠膠囊之膠囊殼。這種膠囊稱為抗胃液性，因為膠囊通過胃通道，並且其內容物僅在腸內釋放。
其填充物位於膠囊殼裡，具有至少一活性成分和任選之不同輔助劑。所述填充物還可以由液體，顆粒，片劑，或(更小)第二膠囊組成。甚至小，且具有抗胃液塗層之，含有對胃酸敏感之成分之丸劑，被封裝在膠囊中。膠囊殼經常亦是有染色，其可保護內容物避免光照，或辨識成單一個別藥物。
根據本發明產品之有利實施例，其膠囊至少包括一塗層，所述之塗層，其可抵抗胃液和/或遮蔽味道。而可作為，例如，可以精確調節其作用時間或作用位置。確保此膠囊經由一抗胃液塗層，可通過胃通道。一掩味塗層，以確保覆蓋該膠囊之某些味道。
根據本發明產品之另一有利實施例，該具有包含GcMAF之配方之乾燥劑型之膠囊，被包含在第二膠囊裡。較佳地，可以經由第二殼
層，精確地調整其作用時間或作用位置。
根據本發明產品之另一有利實施例，所述第二膠囊至少包括一塗層，其可抵抗胃液和/或遮蔽味道。塗層優點已預先提出。
進一步優點和本發明之有利之實施方式，可由以下之描述、申請專利範圍和圖式中獲得。
發明標的之優選實施例如圖所示，並於下被更詳細地說明。圖中所示圖一：試驗001和002之過程參數；圖二：試驗003和004之過程參數；圖三：不同試驗結果分析；圖四：脫脂奶粉之二顯微鏡圖(V003-15/15-080/001)；圖五：微晶纖維素球(Cellets)200之二顯微鏡圖(V003-15/15-080/002)；圖六：已噴霧乾燥GcMAF之一顯微鏡圖(V003-15/15-080/003)；圖七：乳糖之二顯微鏡圖(V003-15/15-080/004)；圖八：一巨噬細胞刺激試驗與在乾燥形式製備之益生菌之說明；圖九：第一醫療成果報告；圖十：第二醫療成果報告；和圖十一：第三醫療成果報告。
實施方式之描述
用於生產含GcMAF配方之乾燥劑型之裝置和方法係基於發酵，及後續之由發酵生成之產物之對流乾燥，由此得到期望之固體劑型。
GcMAF係基於菌原培養物(生物體)經由發酵而產生，其中可以得到所述菌原培養物。發酵進行於原料乳中(類似於製備優酪乳)。用於發酵之微生物以液體形式遞送。此外維生素D3，初乳和油酸單獨地被供應。這些不是傳染性微生物。此供應數量涉及到100升之發酵批料。這亦適用於維生素D3，初乳和油酸。此外，牛奶，較佳為要求有機牛奶，例如：Demeter-Bauern(品牌)牛奶。其發酵過程不在燻蒸或持續攪拌下進行。牛奶一開始與添加劑攪拌。之後此發酵批料被放置2天，於恆溫37℃。在此過程中，產生優格型式。在發酵過程中無須取樣。最終產品應存放在陰涼處。此處，發酵於一反應器(生物反應器/發酵罐)中發生。該反應器可以被燻蒸，攪拌及/或調節。
以下所列是根據1000毫升牛奶之發酵組合物之列表：
5.7克 初乳(Colostrum)
乳酸桿菌，6 x 109CFU(菌落形成單位)
唾液乳酸桿菌
嗜酸乳酸桿菌2x
副乾酪乳酸
鼠李糖乳酸桿菌
保加利亞乳桿菌
雙歧桿菌，3 x 109CFU(菌落形成單位)
兩歧雙歧桿菌(Bifidobacterium bifidum)
長雙歧桿菌(Bifidobacterium longum)
動物雙歧桿菌(Bifidobacterium animalis)
青春雙歧桿菌(Bifidobacterium adolescentis)
短雙歧桿菌(Bifidobacterium breve)
嬰兒雙歧桿菌(Bifidobacterium infantis)
雙歧桿菌(雷特氏B菌)(Bifidobacterium lactis)
乳酸乳桿菌，2 x 109CFU(菌落形成單位)
腸膜明串珠菌乳脂亞種(Leuconostoc mesenteroides subsp.Cremoris)，1 x 109CFU(菌落形成單位)
酵母菌
克魯維酵母(Klyveromyces)，1 x 109
釀酒酵母(Saccharomyces)，1 x 109
醋桿菌(Acetobacter)，1 x 109
嗜熱鏈球菌(Streptococcus thermophilus)，1 x 109(菌原)
微粉化(乾燥)之生物質應當達到容易攝取之效果，例如：
舌頭(舌下)，其粒徑在微米範圍內。為此目的，準備測試該功效之樣品材料。微粉化方法已被提出，以防止通過胃通道。
可選擇地，生物質之分層，係進行於菌原核心上，例如：Cellet 200或其類似物，而緊接著進行抗胃液塗層(例如蟲膠，Eudragit等)。即，於發酵後，經由對流乾燥(流化床，噴流床，噴霧造粒等)發酵所獲得之產物，以產生一含GcMAF配方之固體劑型。該產生之固體劑型可以通過任何現有方法進行塗層。此外，亦有其它固體劑型給藥方式之可能性，例如作為膠囊劑或類似物。
以下為對流乾燥之若干實施例及其結果：
任務設置
此目標是從經由噴霧造粒乾燥提供之噴霧溶液中回收乾物質。
試驗架構
噴霧造粒乾燥係使用ProCell實驗室與Vario 3設施批次化進行。安排過濾器在層之上，藉由壓縮空氣脈衝之不斷地清洗，使得灰塵得以運回處理室。經由可變速排風扇，處理空氣輸送。使用電加熱器，以加熱空氣。經由底部噴嘴(雙流體噴嘴，冷空氣噴嘴)霧化噴霧液。該噴霧液，經由軟管泵，得以從貯槽被運送(攪動)到噴嘴。
分析方法
造粒乾燥期間，採取產品試樣，使這一過程能夠更好地被判斷。顆粒分析之進行，係使用光學圖像評估系統(Camsizer-Retsch)。對於樣品之光學評估係經由蔡司AXIO顯微鏡執行。
試驗執行與結果
該試驗，於沒有客戶之情況下進行。在附件中之重要製程參數之趨勢曲線係描述試驗條件。該分析及顯微鏡圖片闡明其結果。
試驗001和002顯示於圖1，試驗003和004顯示於圖2。
V003-15/15-080/001
對於第一實驗，取1000克脫脂奶粉作為初始原料。使用Ultra-Turrax攪拌器以3000轉/分，攪拌兩分鐘，使噴霧液得以噴灑。1000克噴霧液被施加到脫脂奶粉。進行攪拌同時，黃色奶油物料沉積在表面上。而此實驗可以繼續進行，沒有進一步之問題。
V003-15/15-080/002
在第二實驗中，取1000克Cellets 200，並開始噴塗。其再次以1000克噴霧液施加。
V003-15/15-080/003
在第三實驗中，進行噴霧乾燥。安裝新產品過濾器並在無模板物質下，啟動噴灑。所得乾燥產物在實驗結束後從該容器壁和過濾器取下。已噴射1600克噴霧液。
V003-15/15-080/004
在第四實驗中，取500克乳糖。不同於先前之實驗，該噴霧液於連續攪拌被加熱至35℃。如所預期，黃色奶油物料分解，並形成一均勻噴霧液。1127克被噴灑到乳糖。該試驗得到之粒徑達到d50=178.6μm。
結論
如果呈現一合適之初始填料，所述之噴霧造粒乾燥係為相當可行。
合適之載體材料為奶粉、乳糖和Cellets，以進行測試。而其他載體材料是可設想和具有其適用性。圖4至7顯示出個別塗層之載體材料。
噴霧液加熱到35℃，以便實現產品之均勻性。
無模板材料之啟動，在未來亦具可能性。其必須在開始過程時，被中斷數次。乾物質形成，隨後從容器壁刮下，使流化床漸漸形成。執行此類實驗，提供約500克乾物質之噴霧溶液。
圖8顯示以所裝備之乾燥形式之益生菌對巨噬細胞刺激試驗，其具有之說明。該研究在一標準化之巨噬細胞刺激試驗下，進行乾燥益生菌對巨噬細胞活性之效果。為此目的，三種不同之血液樣品被測試，其顯示於圖9至11。由TNF-α之滴定測量，不約而同地，所有血液樣品顯示其巨噬細胞活性顯著。因此可以認為，該乾燥質地益生菌，發揮高生物活性免疫調節作用。
一般性過程或程序上方法，係由培養物(混合物)之發酵及隨後之對流乾燥之組合所組成，用以製備一穩定或固定長期穩定之固體形式。其乾燥產物可進行不同之調節。
該過程之工程解決方案意在體現一衛生安全之過程，譬如一切都可以在此進行封裝(GMP環境係容易實現)。此外，可容易進行過程控制。由於同時具能源需求低，與最佳之產品安全性，其可達成一具有成本效益，之用於生產含GcMAF配方之乾燥劑型之方法。
熱對流乾燥可以例如，經由一流化床、噴流床或噴霧乾燥得以實現，其得以接觸式乾燥替代。然而，此情況下，可無此方式定義之流程管理。冷凍乾燥具有未定義之產品結構和高處理成本費用之不利性。
所有本文所述之特徵，不論個別地和彼此之任意組合，為本發明所必要。
Claims (9)
- 一種片劑，其特徵為，該片劑由包含GcMAF之配方之乾燥劑型所組成。
- 根據申請專利範圍第1項所述之方法，其特徵為，該片劑包括至少一塗層。
- 根據申請專利範圍第2項所述之方法，其特徵為，該至少一塗層係抗胃液及/或味道遮蔽。
- 一種包括一膠囊殼和一填充物之膠囊，其特徵為，該填充物係含GcMAF之配方之乾燥劑型。
- 根據申請專利範圍第4項所述之方法，其特徵為，該膠囊包括至少一塗層。
- 根據申請專利範圍第5項所述之方法，其特徵為，該至少一塗層係抗胃液及/或味道遮蔽。
- 根據申請專利範圍第4項至第6項其中一項所述之方法，其特徵為，具有包含GcMAF之配方之乾燥劑型之該膠囊，被包含在一第二膠囊裡。
- 根據申請專利範圍第7項所述之方法，其特徵為，該第二膠囊包括至少一塗層。
- 根據申請專利範圍第8項所述之方法，其特徵為，該第二膠囊之該至少一塗層係抗胃液及/或味道遮蔽。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015014575 | 2015-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201722462A true TW201722462A (zh) | 2017-07-01 |
Family
ID=57391718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105135918A TW201722984A (zh) | 2015-11-05 | 2016-11-04 | 用於生產含ＧｃＭＡＦ配方之乾燥劑型之方法及裝置 |
| TW105135919A TW201722462A (zh) | 2015-11-05 | 2016-11-04 | 具有包含GcMAF之配方之乾燥劑型之片劑形式或膠囊形式之產品 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105135918A TW201722984A (zh) | 2015-11-05 | 2016-11-04 | 用於生產含ＧｃＭＡＦ配方之乾燥劑型之方法及裝置 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3371319B1 (zh) |
| CN (1) | CN108350477A (zh) |
| DE (2) | DE102016121050A1 (zh) |
| TW (2) | TW201722984A (zh) |
| WO (2) | WO2017076397A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102019211195A1 (de) * | 2019-07-26 | 2021-01-28 | Add Advanced Drug Delivery Technologies Ltd. | Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100118164A (ko) * | 2009-04-28 | 2010-11-05 | 우송대학교 산학협력단 | 유산균 수가 많으면서 저장성 및 흐름성이 우수한 과립형 요쿠르트 제조방법 |
| JP5686680B2 (ja) * | 2011-06-24 | 2015-03-18 | カルピス株式会社 | 乳酸菌発酵によるカゼイン由来ペプチドの製造方法 |
| WO2014199373A1 (en) * | 2013-06-09 | 2014-12-18 | Efranat Ltd. | Compositions comprising gc- macrophage activating factor and uses thereof |
-
2016
- 2016-11-04 WO PCT/DE2016/100522 patent/WO2017076397A1/de active Application Filing
- 2016-11-04 DE DE102016121050.1A patent/DE102016121050A1/de not_active Withdrawn
- 2016-11-04 TW TW105135918A patent/TW201722984A/zh unknown
- 2016-11-04 EP EP16801701.0A patent/EP3371319B1/de not_active Not-in-force
- 2016-11-04 TW TW105135919A patent/TW201722462A/zh unknown
- 2016-11-04 DE DE102016121061.7A patent/DE102016121061A1/de not_active Withdrawn
- 2016-11-04 CN CN201680064522.5A patent/CN108350477A/zh active Pending
- 2016-11-04 WO PCT/DE2016/100521 patent/WO2017076396A1/de active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN108350477A (zh) | 2018-07-31 |
| DE102016121061A1 (de) | 2017-05-11 |
| TW201722984A (zh) | 2017-07-01 |
| EP3371319B1 (de) | 2019-07-17 |
| DE102016121050A1 (de) | 2017-05-11 |
| WO2017076397A1 (de) | 2017-05-11 |
| EP3371319A1 (de) | 2018-09-12 |
| WO2017076396A1 (de) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Bioinspired oral delivery devices | |
| AU2017299137B2 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| CN110075130A (zh) | 益生生物和/或治疗剂的靶向胃肠道递送 | |
| KR20150034243A (ko) | 프로바이오틱 캡슐화용 마이크로입자, 그의 제조 및 이용 | |
| JP6637725B2 (ja) | ウイルス感染症の予防及び／又は治療剤 | |
| EP3442547B1 (en) | Lactobacillus reuteri mm4-1a for use in the treatment or prevention of autism spectrum disorders | |
| TW201803576A (zh) | 以新生兒為對象的腦功能改善用組成物 | |
| KR20180101491A (ko) | 락토바실러스 플란타룸의 신규한 프로바이오틱 박테리아 균주 및 조성물 그리고 염증 치료에 있어서 이들의 용도 | |
| Pyar et al. | Enteric coating of granules containing the probiotic Lactobacillus acidophilus | |
| KR20210003138A (ko) | 내습성 프로바이오틱 과립 및 그의 제조 방법 | |
| CN112121067A (zh) | 一种婴儿型双歧杆菌微胶囊及其制备方法 | |
| TW201902499A (zh) | 用於類鐸受體２活性化之組成物 | |
| TWI334355B (en) | Method for preparing an orally administrable formulation for controlled release and orally administrable formulation | |
| CN105435213A (zh) | 利用乳铁蛋白治疗或预防幽门螺旋杆菌感染的方法 | |
| TW201722462A (zh) | 具有包含GcMAF之配方之乾燥劑型之片劑形式或膠囊形式之產品 | |
| JP5907796B2 (ja) | 腸内環境改善食品 | |
| JP2012188409A (ja) | 消化管痛の予防又は軽減剤 | |
| TW201138651A (en) | Agent for controlling the increase and decrease of lactobacillus bifidus in colon | |
| JP5631721B2 (ja) | 胃腸機能亢進剤 | |
| JP6402016B2 (ja) | 神経機能改善剤 | |
| CN116270529B (zh) | 一种靶向治疗幽门螺杆菌的类人体纳米微囊制剂及其制备方法和应用 | |
| RU2780868C1 (ru) | Иммунобиологическое средство на основе бутирата и способ его использования для терапии воспалительных заболеваний кишечника | |
| Andrusyak et al. | Influence of the bee products on commercial and clinical strains of probiotic cultures | |
| Ullah et al. | Prebiotics and Probiotics: Concept and Advances | |
| WO2021258209A1 (en) | Composite coating for an active agent |